Navigation Links
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Date:4/17/2008

egenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertain
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
(Date:7/31/2014)... , July 31, 2014 For its innovative ... California , Art,s-Way Scientific has earned a Modular ... With competition in over 30 categories, MBI,s contest is ... members, which include building manufacturers, dealers, and product and ... excellent example the capability of our team," said ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... 29 Pfizer Inc. (NYSE: PFE ) invites investors and the general ... at 10 a.m. EDT on Tuesday, August 3, 2010 . The purpose ... company,s Second Quarter 2010 Performance Report, to be issued that morning. , ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) , , , ...
... , SUNNYVALE, Calif. , June 29 Accuray Incorporated ... announced today the appointment of Peter Fine as a member of ... replace board member Li Yu who has resigned effective June ... Fine currently serves ...
Cached Medicine Technology:Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts 2Accuray Appoints Peter Fine to Board of Directors 2Accuray Appoints Peter Fine to Board of Directors 3Accuray Appoints Peter Fine to Board of Directors 4
(Date:8/1/2014)... Seattle, Wa (PRWEB) August 01, 2014 ... Sores Fast book review recently updated by Vkool.com, ... remedies for relieving symptoms of cold sores ... in the neck ,     A sore throat ... ,     Eating, drinking, and sleeping are uncomfortable ...
(Date:8/1/2014)... WA (PRWEB) August 01, 2014 Blindness is ... be argued that the scientists of today, despite well-meaning efforts, ... to providing a definite treatment for reversing blindness that does ... that sense, this is where alternative medicine takes the “slack” ... rely on expensive treatments or harmful surgeries. , Alternative ...
(Date:8/1/2014)... 01, 2014 Fitness is something most people ... From walking around the block to biking ten or more ... easy to maintain throughout the year. The Forbes Living ... series which will feature special guests, tips to get started ... shape. The series will air on most popular cable television ...
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... Stress management can be difficult in this day and ... diminish rest and leisure time, stress can mount up and ... a way to manage stress in order to be healthy ... good sense of work-life balance is the key to managing ... of SF Custom Chiropractic. “Stress, left unchecked, can not only ...
Breaking Medicine News(10 mins):Health News:Get Rid Of Cold Sores Fast Book Review Exposes Ellie Gadsby's Guide For Treating Fever Blisters – Vkool.com 2Health News:Get Rid Of Cold Sores Fast Book Review Exposes Ellie Gadsby's Guide For Treating Fever Blisters – Vkool.com 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:Forbes Living to Air Fitness Forward Series 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2
... Postgraduate Services® (PPS®), renowned for its ... of an on-demand, interactive case study, ... Options for Mid-Face Volumizing, now available ... Applications explores treatment options for the ...
... Data Manipulation , ... Denver, CO (PRWEB) July 8, ... based in Melbourne, FL, has just recorded its 30th year in ... and data manipulation in particular. IRI's flagship CoSort product is used ...
... Only the Best Medical Travel Agencies , ... Vernon Hills, Illinois (PRWEB) ... up in the U.S., more and more medical tourism agencies (MTAs) are ... should be aware that not all MTAs are created equally. According to ...
... trials to recruit large percentage of African American ... ... can double,a person,s weight loss according to a study from Kaiser Permanente,s ... weight loss maintenance trials ever conducted, will be published in,the August issue ...
... -- hailed since their inception in 2000 as ... resulting in members forgoing care and discontinuing drugs ... newly published studies. , Under employer-offered CDHPs, members ... dedicated health-care account before insurance coverage begins. Proponents ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... report results for its fourth quarter and,fiscal year 2008, ... after,the market closes., A conference call to review ... EDT) and will be hosted by Euan S. Thomson, ...
Cached Medicine News:Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 2Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 3Health News:IRI, The CoSort Company, Marks 30 Years 2Health News:IRI, The CoSort Company, Marks 30 Years 3Health News:An American Appeal to Overseas Hospitals 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 4Health News:Members of consumer-driven health plans choosing less care 2Health News:Accuray Incorporated to Report Fourth Quarter and Fiscal Year 2008 Financial Results 2
For the quantitative determination of high density lipoprotein (HDL) in human serum....
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Medicine Products: